LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Elenco Azioni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Chiusa

28.33 2.09

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.75

Massimo

28.44

Metriche Chiave
By Trading Economics
Entrata	43M 13M
Vendite	29M 107M
EPS	0.25
Margine di Profitto	12.139
Dipendenti	524
EBITDA	16M 8.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+122.21% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	18M 1.5B
Apertura precedente	26.24
Chiusura precedente	28.33

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

27.895 / 30.16 Supporto e resistenza

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2026, 23:10 UTC

Azioni calde

Stocks to Watch: Agilysys, XP

18 mag 2026, 18:44 UTC

I principali Market Mover

Claritev Shares Recover After Comments About DOJ

18 mag 2026, 23:55 UTC

Utili

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mag 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

18 mag 2026, 20:25 UTC

Utili

Correct: XP 1Q Total Client Assets BRL1.53T

18 mag 2026, 20:23 UTC

Utili

XP 1Q Total Client Assets BRL1.53B

18 mag 2026, 20:19 UTC

Utili

XP 1Q Adj EPS BRL2.49 >XP

18 mag 2026, 20:19 UTC

Utili

XP 1Q Rev BRL4.73B >XP

18 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mag 2026, 19:00 UTC

Utili

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mag 2026, 18:52 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mag 2026, 18:17 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mag 2026, 17:22 UTC

Discorsi di Mercato

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mag 2026, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mag 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mag 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Buys Canada's Modern Group of Companies

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

122.21% in crescita

Previsioni per 12 mesi

Media 62.33 USD 122.21%

Alto 100 USD

Basso 33 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.